Los Angeles, Calif. — Immix Biopharma, Inc, a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that the European Commission (EC) has granted orphan drug designation to NXC-201 for the treatment of AL Amyloidosis. “European Union orphan drug designation for NXC-201 represents an important milestone in our...
Latest News
LOS ANGELES, CA — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced positive phase 2 NXC-201 results in an oral presentation at ASH 2025 presented by Heather Landau, MD, of Memorial Sloan Kettering Cancer Center. NXC-201 demonstrated a complete...
LOS ANGELES — Immix Biopharma, Inc. (Nasdaq:IMMX), a clinical-stage biopharmaceutical company advancing personalized therapies for oncology and immunology, today announced that it will host a virtual KOL event to discuss its BCMA-Targeted CAR-T cell therapy candidate NXC-201, in development for relapsed/refractory AL amyloidosis (R/R ALA) and relapsed/refractory multiple myeloma (R/R...
LOS ANGELES, Calif. — ImmPACT Bio USA Inc. (ImmPACT Bio), a clinical-stage biopharmaceutical company developing a new generation of cellular therapies that have the potential to bring transformational benefits to patients, today announced the United States Food and Drug Administration (FDA) has cleared an investigational new drug application (IND) for...
Utrecht, Netherlands – A detailed ‘atlas’ of neuroblastoma tumors points to a new target for immunotherapy. Scientists from the Princess Máxima Center for pediatric oncology in the Netherlands mapped this childhood tumor at the level of individual cancer and immune cells. In doing so, they discovered a brake on the...
PALO ALTO, Calif. — Immune-Onc Therapeutics Inc., a clinical-stage biopharmaceutical company advancing novel therapies in immunology and oncology by targeting myeloid cell inhibitory receptors, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for IO-202 for the treatment of chronic myelomonocytic leukemia (CMML). IO-202...
PALO ALTO, Calif. – Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints, today announced the appointment of Stuart Lutzker, M.D., Ph.D. to Immune-Onc’s Scientific Advisory Board (SAB). A pioneer of the biotech industry, Dr. Lutzker brings decades of oncology drug discovery and...
NEW YORK, NY — Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced positive updated survival and safety data from its ongoing Phase 2a trial of atebimetinib (IMM-1-104) in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients (N=34), with 9 months...
NEW YORK, NY — Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it is on track to dose the first patient in its planned global Phase 3 registrational trial in first line pancreatic cancer patients in...
CAMBRIDGE, Mass. — Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for its lead clinical-stage program, IMM-1-104, for the treatment of patients with...